EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Resistance to HIV-1 Entry Inhibitors

W C Olson, P J Maddon

Current Drug Target -Infectious Disorders · 01.12.2003 · 3 (4) · 283-294

DOI: 10.2174/1568005033481015 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Drug Target -Infectious Disorders, erschienen am 01.12.2003. Verfasst von W C Olson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Progenics Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. olson@progenics.com. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance-testing technology has been incorporated into the standard of care for human immunodeficiency virus type 1 (HIV-1) infection and therapy with protease and reverse transcriptase inhibitors. Inhibitors of HIV-1 entry represent an emerging mode of antiretroviral therapy, and HIV-1 entry inhibitors encompass three mechanistically distinct classes of agents known as attachment inhibitors, coreceptor inhibitors, and fusion inhibitors. Each class of agent has demonstrated promise in controlled clinical trials, and understanding the determinants and evolution of viral resistance will be critical for the optimal development and deployment of these new treatment classes. Advances in resistance-testing technologies have paralleled the development of HIV-1 entry inhibitor therapies, and the available data support the notion that attachment, coreceptor and fusion inhibitors offer complementary modes of therapy and distinct resistance profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmidesAnti-HIV AgentsBenzylaminesCD4 ImmunoadhesinsCyclamsDrug Resistance, ViralEnfuvirtideHIV Envelope Protein gp41HIV InfectionsHIV-1Heterocyclic CompoundsHumansPeptide FragmentsPiperazinesQuaternary Ammonium Compounds

Substanzen

AmidesAnti-HIV AgentsBMS 806BenzylaminesCD4 ImmunoadhesinsCD4-IgG(2)CyclamsHIV Envelope Protein gp41Heterocyclic CompoundsPeptide Fragments

Autor:innen und Institutionen

  • Progenics Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. olson@progenics.com

Förderung

  • NIAID NIH HHS

Zitieren

APA

Olson, W. C., & Maddon, P. J. (2003). Resistance to HIV-1 Entry Inhibitors. Current Drug Target -Infectious Disorders, 3(4), 283-294. https://doi.org/10.2174/1568005033481015

Vancouver

Olson WC, Maddon PJ. Resistance to HIV-1 Entry Inhibitors. Current Drug Target -Infectious Disorders. 2003;3(4):283-294. doi:10.2174/1568005033481015

BibTeX
@article{Olson2003,
  author = {Olson, W C and Maddon, P J},
  title = {Resistance to HIV-1 Entry Inhibitors},
  journal = {Current Drug Target -Infectious Disorders},
  year = {2003},
  volume = {3},
  number = {4},
  pages = {283--294},
  doi = {10.2174/1568005033481015}
}
Kostenlos starten →